Results 191 to 200 of about 120,695 (300)

Syphilitic Alopecia

open access: yesInternal Medicine, 2013
David A, Wetter, Gregory P, Henderson
openaire   +3 more sources

The Gut Microbiome as a Therapeutic Target in Alopecia Areata: Not Yet Part of the Patient Treatment Plan

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Interest in the gut microbiome as a therapeutic target for treating alopecia areata (AA) has grown considerably. However, existing evidence remains limited and inconsistent. Currently, there is insufficient evidence to recommend microbiome‐directed testing and therapies to patients with AA.
Eric McMullen   +9 more
wiley   +1 more source

Addiction and chronic skin diseases: A Pan‐European study on prevalence, associations and patient impact

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This pan‐European study reveals high rates of addiction in patients with chronic skin diseases. Smoking, alcohol, drug use, gambling, and internet addiction were prevalent and associated with quality of life, demographics, and region. The findings support integrating addiction screening into dermatologic care to improve outcomes.
Stefanie Ziehfreund   +73 more
wiley   +1 more source

Lichen Planopilaris Induced by Checkpoint Inhibitors: A Systematic Review

open access: yes
International Journal of Dermatology, EarlyView.
Niyoosha Yoosefi   +2 more
wiley   +1 more source

Family quality‐of‐life burden in chronic spontaneous urticaria: A multicentre study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Poor control of chronic spontaneous urticaria (CSU) significantly worsens family members' quality of life, especially in emotional, physical, and social domains. Higher disease severity was linked to increased caregiving burden and household expenditures, highlighting the need for family‐centred CSU care and support across diverse global populations ...
Beatrice Martinez Zugaib Abdalla   +33 more
wiley   +1 more source

Litifilimab efficacy on skin outcomes in cutaneous lupus erythematosus in the Phase 2 LILAC study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Our findings show that greater proportions of litifilimab‐treated participants than placebo experienced 20%, 50%, 70% or 90% improvements in CLASI‐A score from baseline and CLASI‐A scores of 0–1 or 0–3. Similar results were observed using physician global assessments, supporting the Phase 2 LILAC study primary analysis in CLE.
Victoria P. Werth   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy